MDGL
HOLD / NEUTRALMeanRevComposite
54.80
Technical
53.50
Fundamental
55.30
Rank
—
Price
493.11
Hurst
0.29
As of
Jul 31, 2026
Daily
Madrigal Pharmaceuticals, Inc.
HealthcareBiotechnologyMadrigal Pharmaceuticals is a biotech firm that develops treatments for metabolic dysfunction-associated steatohepatitis, a liver disease. The company's primary product is Rezdiffra, which works as a thyroid hormone receptor beta agonist designed specifically to address this condition. Founded in 2016 and based in Pennsylvania, the company operates in the United States market.
Market cap
$9.9B
P/E (trailing)
—
P/E (forward)
44.63
PEG ratio
—
Dividend yield
0.00%
Beta
-1.05
52w range
399.00 – 615.00
Return on equity
-53.31%
Profit margin
-25.32%
Revenue growth
+71.20%
Earnings growth
—
Price history
1Y: 429.61 (+0.5%) · range 412.35–602.83
Cycle position
23/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 79 · GOOD SETUP · exit proximity 0
Conviction
48/ 100 · maturity 0%
Buildup.333
EMA entry setup.4279
Fundamentals.2555
Volume profile
POC
516.00
Price vs POC
-16.7%
Overhead supply
99%
Runway
+18.1%
Value area 488.55–552.11 · 99% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +14.22% | +16.34% | mature |
| 40d | +10.64% | +17.04% | mature |